KALA BIO, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
KALA BIO, INC. (KALA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$5.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-04-15
- KALA BIO, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$5.73M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$5.73M 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |